Cantillon Capital Management LLC Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Cantillon Capital Management LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 12.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,066,144 shares of the medical research company’s stock after acquiring an additional 226,017 shares during the quarter. IQVIA comprises approximately 2.5% of Cantillon Capital Management LLC’s portfolio, making the stock its 18th biggest position. Cantillon Capital Management LLC owned approximately 1.14% of IQVIA worth $406,018,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of IQV. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA in the third quarter valued at approximately $27,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $33,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. lifted its holdings in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of IQVIA during the third quarter worth $57,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Activity at IQVIA

In other news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on IQV. UBS Group decreased their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. JPMorgan Chase & Co. decreased their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Robert W. Baird decreased their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Trading Up 1.3 %

NYSE:IQV opened at $188.89 on Friday. The company has a market capitalization of $33.26 billion, a PE ratio of 25.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52-week low of $184.66 and a 52-week high of $261.73. The stock has a fifty day simple moving average of $199.13 and a 200-day simple moving average of $214.80.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.